The estradiol pharmacophore: Ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site

Steroids

Volumn 62, Issue 3, 1997, Pages 268-303

  Anstead, Gregory M ^a   Carlson, Kathryn E ^b   Katzenellenbogen, John A ^b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

crystal structure; drug design; estradiol; estrogen receptor; hydrogen bond; ligand, binding site; pharmacophore

Indexed keywords

DRUG CARRIER; ESTRADIOL; ESTRADIOL DERIVATIVE; ESTROGEN RECEPTOR;

ARTICLE; CRYSTAL STRUCTURE; HORMONE RECEPTOR INTERACTION; HORMONE STRUCTURE; HYDROGEN BOND; LIGAND BINDING; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 0031059270     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(96)00242-5     Document Type: Review

References (248)

1. Djerassi C (1989). The bitter pill. Science 245:356-361.
2. Belchetz PE (1994). Drug therapy: Hormonal treatment of post-menopausal women. N Engl J Med 330:1062-1071.
3. Simonsen LLP (1994). Top 200 drugs of 1993: Price of average Rx up only 2.9%. Pharm Times April:18-32.
4. Fevig TL, Katzenellenbogen JA (1987). A short, stereoselective route to 16α-(substituted-alkyl)estradiol derivatives. J Org Chem 52:247-251.
5. Katzenellenbogen BS, Katzenellenbogen BS (1988). Affinity labeling studies of estrogen receptors. In: Gronemeyer H (ed), Affinity Labelling and Cloning of Steroid and Thyroid Hormone Receptors. VCH, Weinheim, Germany, pp. 87-108.
6. Katzenellenbogen JA, Zablocki JA (1987). Cytotoxic oestrogens and antioestrogens: Concepts, progress, and evaluation. In: Furr BJA, Wakeling AE (eds), Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action. Bailliere Tindall, London, pp. 41-59.
7. Cummins CH (1993). Radiolabeled steroidal estrogens in cancer research. Steroids 58:245-259.
8. von Angerer E (1995). The Estrogen Receptor as a Target for Rational Drug Design. R.G. Landes, Austin, TX.
9. Evans RM (1988). The steroid and thyroid hormone receptor supertamily. Science 240:889-895.
10. Green S, Choubow P (1991). The oestrogen receptor: from perception to mechanism. In: Nuclear Hormone Receptors. Parker MG, Ed. Academic Press, London, Chapt. 2, pp. 15-38.
11. Gronemeyer H, Laudet V (1995). Transcription Factors 3: Nuclear Receptors. In: Protein Profiles, Vol. 2, (Sheterline P, Ed.) Academic Press, London, pp. 1173-1308.
12. Zeelen FJ (1990). Medicinal Chemistry of Steroids. Elsevier, Amsterdam.
13. Pakdel F, Le Gac F, Le Goff P, Valotaire Y (1990). Full-length sequence and in vitro expression of rainbow trout estrogen receptor cDNA. Mol Cell Endocrinol 71:195-204.
14. Koike S, Sakai M, Muramatsu M (1987). Molecular cloning and characterization of rat estrogen receptor cDNA. Nucleic Acids Res 15:2499-2513.
15. White R, Lees JA, Needham M, Ham J, Parker M (1987). Structural organization and expression of the mouse estrogen receptor. Mol Endocrinol 1:735-744.
16. Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, Chambon P (1986). Human oestrogen receptor cDNA: Sequence, expression and homology to v-erb-A. Nature 320:134-139.
17. Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J (1986). Sequence and expression of human estrogen receptor complementary DNA. Science 231:1150-1154.
18. Krust A, Green S, Argos P, Kumar V, Walter P, Bornert JM, Chambon P (1986). The chicken oestrogen receptor sequence: Homology with v-erbA and the human oestrogen and glucocorticoid receptors. EMBO J 5:891-897.
19. Bökenkamp D, Jungblut PW, Thole HH (1994). The C-terminal half of the porcine estradiol receptor contains no post-translational modification: determination of the primary structure. Mol Cell Endocrinol 104:163-172.
20. Schwabe JWR, Chapman L, Finch JT, Rhodes D, Neuhaus D (1993). DNA recognition by the oestrogen receptor: From solution to the crystal. Structure 1:187-204.
21. Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D (1995). Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α. Nature 375:377-382.
22. Renaud J, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras D (1995). Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature 378:681-689.
23. Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD, Fletterick RJ (1995). A structural role for hormone in the thyroid hormone receptor. Nature 378:690-697.
24. Wurtz J-M, Bourguet W, Renaud J-P, Vivat V, Chambon P, Moras D, Gronemeyer H (1996). A canonical structure for the ligand-binding domain of nuclear receptors. Nature Struct Biol 3:87-94.
25. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS (1996). Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell-and promoter-specific action of these hormones. Mol Endocrinol 10: 119-131.
26. Katzenellenbogen JA, Katzenellenbogen BS (1996). Nuclear hormone receptors: Ligand-activated regulators of transcription and diverse cell responses. Chem Biol 3:529-536.
27. Anstead GM, Kym PR (1995). Predicted carcinogenicity and structure-estrogen receptor binding affinities of benz[a]anthracene diols. Steroids 60:383-394.
28. Murphy KP, Freire E (1992). Thermodynamics of structural stability and cooperative folding behavior in proteins. Adv Protein Chem 43:313-361.
29. Testa B, Jenner P, Kilpatrick GJ, El Tayar N, Van de Waterbeemd H, Marsden CD (1987). Do thermodynamic studies provide information on both the binding to and the activation of dopaminergic and other receptors? Biochem Pharmacol 23:4041-4046.
30. Katzenellenbogen JA, Heiman DF, Carlson KE, Lloyd JE (1982). In vivo and in vitro steroid receptor assays in the design of estrogen pharmaceuticals. In: Eckelman WC (ed), Receptor-Binding Radiotracers, Vol. I. CRC, Boca Raton, Florida, pp. 93-126.
31. Pomper MG, Van Brocklin ZH, Thieme A, Thomas RD, Kiesewetter DO, Carlson KE, Mathias CJ, Welch MJ, Katzenellenbogen JA (1990). 11β-Methoxy, 11β-ethyl, and 17α-ethynyl-substituted 16α-fluoroestradiols: Receptor-based imaging agents with enhanced uptake efficiency and selectivity. J Med Chem 33:3143-3155.
32. Hospital M, Busetta B, Bucort R, Weintraub H, Baulieu E-E (1972). X-ray crystallography of estrogens and their binding to receptor sites. Molec Pharmacol 8:438-445.
33. Anstead GM, Peterson CS, Pinney KG, Wilson SR, Katzenellenbogen JA (1990). Torsionally-and hydrophobically modified 2,3-diarylindenes as estrogen receptor ligands. J Med Chem 33:2726-2734.
34. Weeks CM, Cooper A, Norton DA (1970). The crystal and molecular structure of diethylstilbestrol. Acta Crystallog B26:429-432.
35. Duax WL, Griffin JF, Weeks CM, Korach KS (1985). Molecular conformation, receptor binding, and hormone action of natural and synthetic estrogens and antiestrogens. Environ Health Perspect 61:111-121.
36. Dewar MJS, Zoebisch EG, Healy EF, Stewart JJP (1985). AM1: A new general purpose quantum mechanical molecular model. J Am Chem Soc 107:3902-3909.
37. Duax WL, Weeks CM (1980). Molecular basis of estrogenicity: X-ray crystallographic studies. In: McLachlan JA (ed), Estrogens in the Environment. Elsevier North Holland, New York, pp. 11-31.
38. Duax WL, Weeks CM, Rohrer DC (1976). Crystal structures of steroids. Topics Stereochem 9:271-383.
39. Wiese TE, Brooks SC (1994). Molecular modeling of steroidal estrogens: Novel conformations and their role in biological activity. J Steroid Biochem Molec Bio 50:61-73.
40. Andrews PR, Craik DJ, Martin JL (1984). Functional group contributions to drug-receptor interactions. J Med Chem 27:1648-1657.
41. Arányi P (1980). Kinetics of the hormone-receptor interaction. Competition experiments with slowly equilibrating ligands. Biochim Biophys Acta 628:220-227.
42. Bouton MM, Raynaud JP (1978). The relevance of kinetic parameters in determination of specific binding to the estrogen receptor. J Steroid Biochem 9:9-15.
43. 3H]estradiol-17β: A very high-affinity, reversible ligand for the estrogen receptor. J Steroid Biochem 28:361-370.
44. d of approximately 10 pM. J Steroid Biochem Molec Biol 50:313-318.
45. Sanborn BM, Rao BR, Korenman SG (1971). Interaction of 17β-estradiol and its specific uterine receptor. Evidence for complex kinetic and equilibrium behavior. Biochemistry 26:4955-4961.
46. King RJB, Mainwaring WIP (1974). Steroid-Cell Interactions. University Park Press, Baltimore, Maryland, p. 192.
47. Eckert RL, Katzenellenbogen BS (1982). Physical properties of estrogen receptor complexes in MCF-7 human breast cancer cells. J Biol Chem 257:8840-8846.
48. Vollmer G, Wünsche W, Schütze N, Feit B, Knuppen R (1991). Methyl and bromo derivatives of estradiol are agonistic ligands for the estrogen receptor of MCF-7 breast cancer cells. J Steroid Biochem Molec Biol 39:359-366.
49. Lövgren T, Pettersson K, Kouvonen I, Punnonen R (1978). Binding characteristics of estrone, estradiol, and estriol to the human myometrial receptor. J Steroid Biochem 9:803-809.
50. Ratajczak T, Sheppard PN, Capon RJ, Hähnel R (1981). The synthesis and study of some potential affinity labeling reagents for estrogen receptors. Steroids 38:537-555.
51. Fanchenko ND, Sturchak SV, Shchedrina RN, Pivnitsky KK, Novikov EA, Ishkov VL (1979). The specificity of the human estrogen receptor. Acta Endocrin (Copenh) 90:167-175.
52. Daniellian PS, White R, Hoare SA, Fawell SE, Parker MG (1993). Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. Molec Endocrin 7:232-240.
53. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA (1996). Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925-5930.
54. Keasling HH, Schueler FW (1950). The relationship between estrogenic action and chemical constitution in a group of azomethine derivatives. J Am Pharm Assoc 39:87-90.
55. Ojasoo T, Raynaud J-P, Doré J-C (1995). Correspondence factor analysis of steroid libraries. Steroids 60:458-469.
56. Delettré J, Mornon JP, Lepicard G, Ojasoo T, Raynaud JP (1980). Steroid flexibility and receptor specificity. J Steroid Biochem 13: 45-59.
57. Raynaud JP, Ojasoo T, Bouton MM, Bignon E, Pons M, Crastes de Paulet A (1985). Structure-activity relationships of steroidal estrogens. In: McLachlan JA (ed), Estrogens in the Environment II, Elsevier, New York, pp. 24-42.
58. Baker EN, Hubbard RE (1984). Hydrogen bonding in globular proteins. Prog Biophys Molec Biol 44:97-179.
59. Cooper A, Norton DA, Hauptman H (1969). Estrogenic steroids. III. The crystal and molecular structure of estriol. Acta Crystallog B25:814-828.
60. Chernayaev GA, Barkova TI, Egorova VV, Sorokina IB, Ananchenko SN, Mataradze GD, Sokolova NA, Rozen VB (1975). A series of optical, structural and isomeric analogs of estradiol: A comparative study of the biological activity and affinity to cytosol receptor of rabbit uterus. J Steroid Biochem 6:1483-1488.
61. Schwartz JA, Skafar DF (1993). Ligand-mediated modulation of estrogen receptor conformation by estradiol analogs. Biochemistry 32:10,109-10,115.
62. Anstead GM, Wilson SR, Katzenellenbogen JA (1989). 2-Arylindenes and 2-arylindenones: Molecular structures and considerations in the binding orientation of unsymmetrical nonsteroidal ligands to the estrogen receptor. J Med Chem 32:2163-2172.
63. Brooks SC, Wappler NL, Corombos JD, Doherty LM, Horwitz JP (1987). Estrogen structure-receptor function relationships. In: Moudgil VK (ed), Recent Advances in Steroid Hormone Action. Walter de Gruyter, Berlin, pp. 443-466.
64. Busetta B, Hospital M (1972). Structure cristalline et moléculaire de l'oestradiol hemihydrate. Acta Crystallog C43:1206-1209.
65. Busetta B, Courseille C, Geoffre S, Hospital M (1972). Structure cristalline et moléculaire du complexe oestradiol-propanol. Acta Crystallog B28:1349-1351.
66. Duax WL (1972). The structure of the crystalline complex estradiol urea (1:1). Acta Crystallog B28:1864-1871.
67. Legrand M, Delaroff V, Mathieu J (1961). Effet à distance en série stéroïde. II. Influence des fonctions en 17 sur le pK des stéroïdes phénoliques. Bull Soc Chim France 1346-1348.
68. Eik-Nes K, Schellman JA, Lumry R, Samuels LT (1954). The binding of steroids to proteins. I. Solubility determinations. J Biol Chem 206:411-419.
69. Abraham MH, Duce PP, Prior DV, Barratt DG, Morris JJ, Taylor PJ (1989). Hydrogen bonding. Part 9. Solute proton donor and proton acceptor scales for use in drug design. J Chem Soc Perkin Trans II: 1355-1375.
70. Fersht AR, Shi J-P, Knill-Jones J, Lowe DM, Wilkinson AJ, Blow DM, Brick P, Carter P, Waye MMY, Winter G (1985). Hydrogen bonding and biological specificity analyzed by protein engineering. Nature 314:235-238.
71. Feller D, Feyereisen MW (1993). Ab initio study of hydrogen bonding in the phenol-water system. J Comp Chem 14:1027-1035.
72. Kollman PA, Giannini DD, Duax WL, Rothenberg S, Wolff ME (1973). Quantitation of long-range effects in steroids by molecular orbital calculations. J Am Chem Soc 95:2869-2873.
73. Azzi A, Rehse PH, Zhu D-W, Campbell RL, Labrie F, Lin S-X (1996). Crystal structure of human estrogenic 17β-hydroxysteroid dehydrogenase complexed with 17β-estradiol. Nature Struct Biol 3:665-668.
74. + identifies two principal targets for the design of inhibitors. Structures 4:905-915.
75. Gabbard RB, Segaloff A (1983). Structure-activity relationships of estrogens. Effects of 14-dehydrogenation and axial methyl groups at C-7, C-9, and C-11. Steroids 41:791-804.
76. Korenman SG (1969). Comparative binding affinity of estrogens and its relation to estrogenic potency. Steroids 13:163-177.
77. Katzenellenbogen JA, Johnson HJ Jr, Myers HN (1973). Photoaffinity labels for estrogen binding proteins of rat uterus. Biochemistry 12:4085-4092.
78. Martin YC (1979). Advances in the methodology of quantitative drug design. Drug Design VIII:1-72.
79. Street IP, Armstrong CR, Withers SG (1986). Hydrogen bonding and specificity. Fluorodeoxy sugars as probes of hydrogen bonding in the glycogen phosphorylase-glucose complex. Biochemistry 25: 6021-6027.
80. Purdy RH, Maclusky NJ, Naftolin F (1985). Does estrogen-induced genotoxicity require receptor-mediated events? In: McLachlan J (ed), Estrogens in the Environment II, Elsevier Scientific, New York, pp. 146-167.
81. Delettré J, Mornon JP, Ojasoo T, Raynaud JP (1980). An approach to the mapping of the steroid hormone receptor. In: Bresciani F (ed), Perspectives in Steroid Receptor Research. Raven, New York, pp. 1-21.
82. Ippolito JA, Alexander RS, Christianson DW (1990). Hydrogen bond stereochemistry in protein structure and function. J Mol Biol 215:457-471.
83. Thanki N, Thorton JM, Goodfellow JM (1988). Distribution of water around amino acid residues in proteins. J Mol Biol 202:637-657.
84. Antypas WG Jr, Siukola LVM, Kleier DA (1981). Restricted rotation in hydroxyphenyl ketones and formaldehydes. J Org Chem 46:1172-1177.
85. Duax WL, Griffin JF, Rohrer DC, Swenson DC, Weeks CM (1981). Molecular details of receptor binding and hormonal action of steroids derived from X-ray crystallographic investigations. J Steroid Biochem 15:41-47.
86. Weber HP, Galantay E (1972). The crystal and molecular structures of an unusual estrasteroid and its dihydroproduct. Helv Chem Acta 55:544-553.
87. Sampson NS, Knowles JR (1992). Segmental motion in catalysis: Investigation of a hydrogen bond critical for loop closure in the reaction of triosephosphate isomerase. Biochemistry 31:8488-8494.
88. Rupley JA, Careri G (1991). Protein hydration and function. Adv Protein Chem 41:37-172.
89. Busetta B, Courseille C, Precigoux G, Hospital M (1977). Some hypotheses about interactions between estrogen and androgen and their possible receptors. J Steroid Biochem 8:63-67.
90. Tsukuda Y, Sato T, Shiro M, Koyama H (1968). The crystal and molecular structure of oestradiol 3-p-bromobenzoate. J Chem Soc B:1387-1393.
91. Reck G, Schubert G, Bannier G (1986). Crystal and molecular structure of 3-methoxy-estra-1,3,5(10)-triene-17β-ol. Cryst Res Tech 21:1313-1319.
92. Go K, Kartha G, Neeman M (1982). Structure of 4-fluoro-1,3.5(10)-estratriene-3,17β-diol-hemimethanol. Acta Crystallog 838:3142-3144.
93. Norton DA, Kartha G, Lu CT (1964). The crystal and molecular structure of 4-bromoestradiol. Acta Crystallog 17:77-82.
94. Busetta B, Barrans Y, Precigoux G, Hospital M (1976). 1,3,5(10)-Oestradiol-3,17α-diol. Acta Crystallog B32:1290-1291.
95. Meyer E (1992). Internal water molecules and H-bonding in biological macromolecules: A review of structural features with functional implications. Protein Sci 1:1543-1562.
96. Chan SL, Chau P-L, Goodman JM (1992). Ligand atom partial charges assignment for complementary electrostatic potentials. J Comp-Aided Molec Design 6:461-474.
97. Rashin AA, Iofin M, Honig B (1986). Internal cavities and buried waters in globular proteins. Biochemistry 25:3619-3625.
98. Matthews BW, Morton AG, Dahlquist FW (1995). Use of NMR to detect water within nonpolar protein cavities. Science 270:1847-1848.
99. Wade RC, Clark KJ, Goodford PJ (1993). Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 1. Ligand probe groups with the ability to form two hydrogen bonds. J Med Chem 36:140-147.
100. Ben-Naim A, Ting KL, Jernigan RL (1990). Solvent effects on binding thermodynamics of biopolymers. Biopolymers 29:901-919.
101. Raynaud JP, Ojasoo T, Bouton MM, Philibert D (1979). Receptor binding as a tool in the development of bioactive steroids. Drug Design VIII:169-214.
102. Fritsch M, Leary CM, Furlow JD, Ahrens H, Schuh TJ, Mueller GC, Gorski J (1992). A ligand-induced conformational change in the estrogen receptor is localized to the steroid binding domain. Biochemistry 31:5303-5311.
103. Mornon J-P, Delettré J, Lepicard G, Bally R, Surcouf E, Bondot P (1977). Interactions of hormonal steroids: Progestogens. J Steroid Biochem 8:51-62.
104. Schmit J-P, Quivy JI, Rousseau GG (1980). The androgen receptor binding site: Conformational study of steroids in relation with their affinity. I. Interactions with the D-ring. J Steroid Biochem 13: 1387-1394.
105. Kaspar P, Witzel H (1985). Shielding effects at 17α-substituted estrogens. A tentative explanation for low biological activity of 17α-ethyl-estradiol based on IR and NMR spectroscopic studies. J Steroid Biochem 23:611-616.
106. Boobbyer DNA, Goodford PJ, McWhinnie PM, Wade RC (1989). New hydrogen-bond potentials for use in determining energetically favorable binding sites on molecules of known structure. J Med Chem 32:1083-1094.
107. DesJarlais RL, Sheridan RP, Dixon JS, Kuntz ID, Venkataraghavan R (1986). Docking flexible ligands to macromolecular receptors by molecular shape. J Med Chem 29:2149-2153.
108. Ye Y-H, Huang Y-S, Wang Z-Q, Chen S-M, Tian Y (1993). Synthesis of new amino acid and peptide derivatives of estradiol and their binding affinities for the estrogen receptor. Steroids 58: 35-39.
109. Kaspar P, Witzel H (1985). Steroid binding to the cytosolic estrogen receptor from rat uterus. Influence of the orientation of substituents in the 17-position of the 8β-and 8α-series. J Steroid Biochem 23:259-265.
110. Ouellet R, Rousseau J, Brasseur N, van Lier JE, Diksic M, Westera G (1984). Synthesis, receptor binding, and target-tissue uptake of carbon-11 labeled carbamate derivatives of estradiol and hexestrol. J Med Chem 27:509-513.
111. Huheey JE (1978). Inorganic chemistry: Principles of Structure and Reactivity. Harper and Row, New York, p. 267.
112. Peters RH, Crowe DF, Avery MA, Chong WKM, Tanabe M (1989). 17-Desoxy estrogen analogues. J Med Chem 32:1642-1652.
113. Merriam GR, Maclusky NJ, Johnson LA, Naftolin F (1980). 2-Hydroxyestradiol-17α and 4-hydroxyestradiol 17α, catechol estrogens with reduced estrogen receptor binding affinity. Steroids 36: 13-20.
114. Vander Kuur JA, Wiese T, Brooks SC (1993). Influence of estrogen structure on nuclear binding and progesterone receptor induction by the receptor complex. Biochemistry 32:7002-7008.
115. Shutt DA, Cox RI (1972). Steroid and phyto-oestrogen binding to sheep uterine receptors in vitro. J Endocrinol 52:299-310.
116. Hähnel R, Twaddle E, Ratajczak T (1973). The specificity of the estrogen receptor of human uterus. J Steroid Biochem 4:21-31.
117. Gabbard RB, Segaloff A (1983). Structure-activity relationships of 9β-estrogens. Steroids 42:555-563.
118. Müller RE, Wotiz HH (1977). Post-coital contraceptive activity and estrogen receptor binding affinity of phenolic steroids. Endocrinology 100:513-519.
119. Martucci C, Fishman J (1976). Uterine estrogen receptor binding of catecholestrogens and estetrol (1,3,5(10)-estratriene-3,15α,16α,17β-tetrol). Steroids 27:325-333.
120. Lee YJ, Notides AC, Tsay Y-G, Kende AS (1977). Coumestrol, NBD-norhexestrol, dansyl-norhexestrol, fluorescent probes of estrogen-binding proteins. Biochemistry 16:2896-2901.
121. Katzenellenbogen JA, Johnson HJ Jr, Carlson KE, and Myers HN (1974). Photoreactivity of some light-sensitive estrogen derivatives. Use of an exchange assay to determine their photointeraction with rat uterine estrogen binding protein. Biochemistry 13:2986-2994.
122. Dandliker WB, Brawn RJ, Hsu M-L, Brawn PN, Levin J, Meyers CY, Kolb VM (1978). Investigation of hormone-receptor interactions by means of fluorescent labeling. Cancer Res 38:4212-4223.
123. Ali H, van Lier JE (1991). Synthesis and receptor binding affinity of 7α-and 17α-substituted 2-and 4-chloroestradiol derivatives. J Chem Soc Perkin 1:2485-2491.
124. Swaneck GE, Fishman J (1988). Covalent binding of the endogenous estrogen 16α-hydroxyestrone to estradiol receptor in human breast cancer cells: Characterization and intranuclear localization. Proc Natl Acad Sci USA 85:7831-7835.
125. Salman M, Reddy BR, Ray S, Stotter PL, Chamness GC (1986). 17α-Allyl estradiol analogues as candidates for development of high-affinity fluorescein-estradiol conjugates. J Steroid Biochem 24:539-548.
126. Salman M, Reddy BR, Delgado P, Stotter PL, Fulcher LC, Chamness GC (1991). 17α-Substituted analogs of estradiol for the development of fluorescent estrogen receptor ligands. Steroids 56: 375-387.
127. Gale MM, Saunders L (1971). The solubilisation of steroids by lysophosphatidylcholine: Testosterone, estradiol, and their 17α-ethinyl derivatives. Biochim Biophys Acta 248:466-470.
128. Moriguchi I, Kanada Y, Komatsu K (1976). van der Waals volume and the related parameters for hydrophobicity in structure-activity studies. Chem Pharm Bull 24:1799-1806.
129. El Garrouj D, Aumelas A, Borgna J-L (1993). Steroidal affinity labels of the estrogen receptor. 1. 17α-(Bromoacetoxy)alkyl/ alkynyl estradiols. J Med Chem 36:2973-2983.
130. Napolitano E, Fiaschi R, Hanson RN (1991). Structure-activity relationships of estrogenic ligands: Synthesis and evaluation of (17α,20E)-and (17α,20Z)-21-halo-19-norpregna-1,3,5(10),20-tetraene-3,17β-diols. J Med Chem 34:2754-2759.
131. Napolitano E, Fiaschi R, Herman LW, Hanson RN (1996). Synthesis and estrogen receptor binding of (17α,20E)-and (17α,20Z)-21-phenythio-and 21-phenylseleno-19-norpregna-1,3,5(10),20-tetraene-3,17β-diols. Steroids 61:384-389.
132. 125I]Iodo-19-norpregna-1,3,5(10),20-tetraene-3,17-diol. J Med Chem 31:1946-1950.
133. Napolitano E, Fiaschi R, Carlson KE, Katzenellenbogen JA (1995). 11β-Substituted estradiol derivatives, potential high-affinity carbon-11-labeled probes for the estrogen receptor: A structure-affinity study. J Med Chem 38:429-434.
134. Ali H, Rousseau J, van Lier JE (1993). Synthesis, receptor binding, and biodistribution of the gem-21-chloro-21-iodovinylestradiol derivatives. J Steroid Biochem Molec Biol 46:613-622.
135. Mazaitis JK, Gibson RE, Komai T, Eckelman WC, Francis B, Reba RC (1980). Radioiodinated estrogen derivatives. J Nucl Med 21:142-146.
136. Arunachalam T, Longcope C, Caspi E (1979). Iodoestrogens, syntheses, and interaction with uterine receptors. J Biol Chem 254: 5900-5905.
137. Hansch L, Leo A (1995). Exploring QSAR. American Chemical Society, Washington, DC, p. 515.
138. 2X-substituierten Östra-1,3,5(10)-trienenen. Pharmazie 30:35-41.
139. Jaouen G, Vessières A, Butler IS (1993). Bioorganometallic chemistry: A future direction for transition metal organometallic chemistry? Acc Chem Res 26:361-369.
140. Vessières A, Vaillant C, Salmain M, Jaouen G (1989). Organometallic derivatives of estradiol as bioligands: Targetted binding of the estradiol receptor. J Steroid Biochem 34:301-305.
141. El Amouri H, Vessières A, Vichard D, Top S, Gruselle M, Jaouen G (1992). Synthesis and affinities of novel organometallic-labeled estradiol derivatives: a structure-affinity relationship. J Med Chem 35:3130-3135.
142. Sadek SA, Kessler WV, Shaw SM, Anderson JN, Wolf GC (1982). Selenium labeling in nuclear medicine. 2. D-ring substituted estrogens. J Med Chem 25:1488-1492.
143. Longcope C, Arunachalam T, Caspi E (1982). The biological activity of selenoestrogens. Can J Biochem 60:152-156.
144. Lam H-YP, Ng PKT, Goldenberg GJ, Wong C-M (1987). Estrogen receptor-binding affinity and cytotoxic activity of three new estrogen-nitrosourea conjugates in human breast cancer cell lines in vitro. Cancer Treat Rept 71:901-906.
145. Delbarre A, Oberlin R, Roques BP, Borgna J-L, Rochefort H, Le Pecq J-B, Jacquemin-Sablon A (1985). Ellipticine derivatives with an affinity to the estrogen receptor. An approach to develop intercalating drugs with a specific effect on the hormone-dependent breast cancer. J Med Chem 28:752-761.
146. Gill JC, Lockey PM, Marples BA, Traynor JR (1986). 3,17β-Dihydroxy-20,21-epoxy-19-norpregna-1,3,5(10)-trienes: synthesis, rearrangement, cytotoxicity, and estrogen-receptor binding. J Med Chem 29:1537-1540.
147. El Garrouj D, Aliau S, Aumelas A, Borgna J-L (1995). Steroidal affinity labels of the estrogen receptor. 2. 17α-[(haloacetamido) alkyl]estradiols. J Med Chem 38:2339-2348.
148. Zeelen FS, Bergink EW (1980). In: Raus J, Martens H, LeClercq G. (eds), Cytotoxic Estrogens in Hormone Receptive Tumors. Academic, London, pp. 39-48.
149. Hähnel R, Twaddle E (1974). The steroid specificity of the estrogen receptor of human breast carcinoma. J Steroid Biochem 5:119-122.
150. Hylarides MD, Duesler EN, Mettler FA, Leon AA (1988). Structural comparison of 1-bromo-and 1-fluoroestradiol with D-estradiol. Acta Crystallog C44:709-712.
151. Heiman DF, Senderhoff SG, Katzenellenbogen JA, Neely RJ (1980). Estrogen receptor based imaging agents. 1. Synthesis and receptor binding affinity of some aromatic and D-ring halogenated estrogens. J Med Chem 23:994-1002.
152. Mukawa F, Suzuki T, Ishibashi M, Yamada F (1988). Estrogen and androgen receptor binding affinity of 10β-chloro-estrenen derivatives. J Steroid Biochem 31:867-870.
153. Katzenellenbogen JA, Katzenellenbogen BS, Tatee T, Robertson DW, Landvatter SW (1980). The chemistry of estrogens and antiestrogens: Relationships between structure, receptor binding, and biological activity. In: McLachlan J (ed) Estrogens in the Environment. Elsevier, North Holland, pp. 33-51.
154. Chesne C, Leclerq G, Pointeau P, Patin H (1986). Synthesis and biological studies of aminoestradiol-platinum (II) conjugates. Eur J Med Chem 21:321-327.
155. Cushman M, He H-M, Katzenellenbogen JA, Lin CM, Hamel E (1995). Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem 38:2041-2049.
156. Qian X-D, Abul-Hajj YJ (1990). Synthesis and biological activity of 4-methylestradiol. J Steroid Biochem 35:745-747.
157. Charton M (1971). The quantitative treatment of the ortho effect. Prog Phys Org Chem 8:235-317.
158. 1,3,5,(10) estratriene compounds. Tetrahedron 29:301-307.
159. Lide DR (ed) (1992). CRC Handbook of Chemistry and Physics. 73rd ed. CRC Press, Boca Raton, Florida, pp. 7-10 and 8-40.
160. Honig B, Nicholls A (1995). Classical electrostatics in biology and chemistry. Science 268:1144-1149.
161. Rochester CH (1971). Acidity and inter-and intra-molecular H-bonds. In: Patai S (ed), The Chemistry of the Hydroxyl Group. Part I. Interscience Publishers, London, pp. 327-392.
162. Leeson PD, Ellis D, Emmett JC, Shah VP, Showel GA, Underwood AH (1988). Thyroid hormone analogues. Synthesis of 3′-substituted 3,5-diiodo-l-thyronines and quantitative structure-activity studies of in vitro and in vivo thyromimetic activities in rat liver and heart. J Med Chem 31:37-54.
163. Dietrich SW, Jorgensen EC, Kollman PA, Rothenberg S (1976). A theoretical study of intramolecular hydrogen bonding in ortho-substituted phenols and thiophenols. J Am Chem Soc 98:8310-8324.
164. Baker AW (1958). On the cis-trans equilibria in o-halophenols. J Am Chem Soc 80:3598-3600.
165. Palomino E, Heeg MJ, Hurwitz JP, Brooks SC (1990). Binding, X-ray, and NMR studies of the three A-ring isomers of natural estradiol. J Steroid Biochem 35:219-229.
166. Napolitano E, Fiaschi R, Hanson RN (1990). Estrogen receptor binding characteristics of 1,11β-ethanoestradiol: Effect of a 1,11β bridge on steroidal estrogen. J Steroid Biochem Molec Biol 37: 295-300.
167. 125I]iodoestradiol derivatives: Synthesis and effect on estrogen receptor binding and receptor-mediated target tissue uptake. J Med Chem 36:4255-4263.
168. Bucort R, Vignau M, Torelli V, Richard-Foy H, Geynet C, Secco-Millet C, Redeuilh G, Baulieu E-E (1978). New biospecific adsorbents for the purification of estradiol receptor. J Biol Chem 253: 8221-8228.
169. Vessières A, Top S, Ismail AA, Butler IS, Louer M, Jaouen G (1988). Organometallic estrogens: Synthesis, interaction with lamb uterine estrogen receptor, and detection by infrared spectroscopy. Biochemistry 27:6659-6666.
170. DiZio JP, Carlson KE, Bannochie CJ, Welch MJ, Von Angerer E, Katzenellenbogen JA (1992). Estrogen platinum-diamine complexes: Preparation of a nonsteroidal estrogen platinum-diamine complex labeled with platinum-191 and a study of its binding to the estrogen receptor in vitro and its tissue distribution in vivo. J Steroid Biochem Mol Biol 42:363-373.
171. Van Aswegen CH, Purdy RH, Wittliff JH (1989). Binding of 2-hydroxyestradiol and 4-hydroxyestradiol to estrogen receptors from human breast cancer. J Steroid Biochem 32:485-492.
172. Martucci CP, Fishman J (1979). Impact of continuously administered catechol estrogens on uterine growth and lutenizing hormone secretion. Endocrinology 105:1288-1292.
173. Wawrzak Z, Duax WL, Strong PD, Weisz J (1988). Steroid structure and function. Molecular conformation of 4-hydroxyestradiol and its relation to other catechol estrogens. J Steroid Biochem 29:387-392.
174. Canceill J, Jacques J, Bouton MM, Fortin M, Tournemine C (1983). Substituted derivatives of A-nor-5α-androstane and A-nor-5α-estrane-structure and affinity for hormonal receptors. J Steroid Biochem 18:643-647.
175. Duax WL, Griffin JF, Rohrer DC, Weeks CM, Ebright RH (1984). Steroid hormone action interpreted from X-ray crystallographic studies. In: Litwack G (ed), Biochemical Actions of Hormones, Vol. XI. Academic, New York, pp. 187-206.
176. Burley SK, Petsko GA (1988). Weakly polar interactions in proteins. Adv Protein Chem 39:125-189.
177. Dougherty DA (1996). Cation-π interactions in chemistry and biology: A new view of benzene, phe. tyr, and trp. Science 271:163-168.
178. Doukas PH (1975). The role of charge-transfer processes in the action of bioactive materials. Drug Design V:133-167.
179. Mauchamp J, Shinitzky M (1969). The nature of thyroxine and related compounds as electron donors. Biochemistry 8:1554-1557.
180. Kearney PC, Mizoue LS, Kumpf RA, Forman JE, McCurdy A, Dougherty DA (1993). Molecular recognition in aqueous media. New binding studies provide further insights into cation-π interaction and related phenomena. J Am Chem Soc 115:9907-9919.
181. Bélanger A, Philibert D, Teutsch G (1981). Regio-and stereospecific synthesis of 11β-substituted 19-norsteroids. Steroids 37:361-382.
182. Napolitano E, Fiaschi R, Carlson KE, Katzenellenbogen JA (1995). 11β-Substituted estradiol derivatives. 2. Potential carbon-11 and iodine-labeled probes for the estrogen receptor. J Med Chem 38:2774-2779.
183. Palomino E, Heeg MJ, Horwitz JP, Polin L, Brooks SC (1994). Skeletal conformations and receptor binding of some 9,11-modified estradiols. J Steroid Biochem Molec Biol 50:75-84.
184. Qian X, Abul-Hajj YJ (1990). Synthesis and biological activities of 11β-substituted estradiol as potential antiestrogens. Steroids 55: 238-241.
185. Schönemann KH, van Vliet NP, Zeelen FJ (1980). Potential anti-tumor agents: 11β-(1-aziridinylmethyl) derivatives of œstradiol and œstrone. Eur J Med Chem 15:333-335.
186. Nique F, van de Velde P, Bremaud J, Hardy M, Philibert D, Teutsch G (1994). 11β-Amidoalkoxyphenyl estradiols. A new series of pure antiestrogens. J Steroid Biochem Molec Biol 50:21-29.
187. Fevig TL, Mao MK, Katzenellenbogen JA (1988). Estrogen receptor binding tolerance of 16α-substituted estradiol derivatives. Steroids 51:471-497.
188. 125I]iodoestradiol with estrogen receptor and other steroid-binding proteins. Proc Natl Acad Sci USA 77:328-332.
189. Hochberg RB, Zielinski JE, Duax WL, Strong P (1986). The molecular structure of 16α-iodo-17β-estradiol, a high affinity ligand for the estrogen receptor. J Steroid Biochem 25:615-618.
190. Van Brocklin HF, Liu A, Welch MJ, O'Neil JP, Katzenellenbogen JA (1994). The synthesis of 7α-methyl-substituted estrogens labeled with fluorine-18; Potential breast tumor imaging agents. Steroids 59:34-45.
191. Ponsold K, Draffehn J, Schönecker B (1977). Quantitative Struktur-Wirkungs-Beziehungen zwischen physikochemischen Paramentern 16α-heterosubstituierter Östradiole und dem Bindungsvermögen an Rezeptoren des Rattenuterus in vitro. Pharmazie 32:596-597.
192. Redeuilh G, Secco C, Baulieu E-E (1985). The use of biotinyl estradiol-avidin system for the purification of "nontransformed" estrogen receptor by biohormonal affinity chromatography. J Biol Chem 260:3996-4002.
193. French AN, Wilson SR, Welch MJ, Katzenellenbogen JA (1993). A synthesis of 7α-substituted estradiols: Synthesis and biological evaluation of 7α-pentyl-substituted BODIPY fluorescent conjugate and a fluorine-18-labeled 7α-pentylestradiol analog. Steroids 58:157-169.
194. Mühlenbruch B, Kirmeier F, Roth HJ (1986). Synthese und Eigenschaften fluoreszierender Estradiol-Derivate. Arch Pharm (Weinheim) 319:196-203.
195. DaSilva JN, van Lier JE (1990). Synthesis and structure-affinity of a series of 7α-undecylestradiol derivatives: A potential vector for therapy and imaging of estrogen-receptor-positive cancers. J Med Chem 33:430-434.
196. Weatherill PJ, Wilson APM, Nicholson RI, Davies P, Wakeling AE (1988). Interaction of the antioestrogen ICI 164,384 with the oestrogen receptor. J Steroid Biochem 30:263-266.
197. Wakeling AE, Bowler J (1992). ICI 182,780, a new antioestrogen with clinical potential. J Steroid Biochem 43:173-177.
198. Katzenellenbogen JA, Carlson KE, Johnson HJ Jr, Myers HN (1976). Chemical probes of estrogen action: Affinity labeling. J Toxicol Environ Health (suppl 1):205-230.
199. Blinkenstaff RP, Gerzon K (1980). Estrogen-Catharanthus (Vinca) alkaloid conjugates. In: Raus J, Martens H, Leclercq G (eds), Cytotoxic Estrogens in Hormone Receptive Tumors. Academic, London, pp. 89-105.
200. Joyce BG, Nicholson RI, Morton SM, Griffiths K (1982). Studies with steroid-fluorescein conjugates on estrogen target tissues. Eur J Clin Oncol 18:1147-1155.158.
201. Duax WL, Smith GD, Swenson DC, Strong PD, Weeks CM, Ananchenko SN, Egorova VV (1981). Steroid structure and function-IX. Molecular conformation and receptor binding of isomeric analogs of D-homo-estradiol. J Steroid Biochem 14:1-7.
202. Bohl M, Schubert G, Koch M, Reck G, Strecke J, Wunderwald M, Prousa R, Ponsold K (1987). Quantitative structure-activity relationships of estrogenic steroids substituted at C14,C15. J Steroid Biochem 26:589-597.
203. Rekker RF, Mannhold R (1992). Calculation of Drug Lipophilicity: The Hydrophobic Fragmental Constant Approach. VCH, Weinheim, Germany, pp. 77-84.
204. Westphal U (1971). Steroid-Protein Interactions. Springer-Verlag, New York, p. 108.
205. Eriksson AE, Baase WA, Zhang X-J, Heinz DW, Blaber M, Baldwin EP, Matthews BW (1992). Response of protein structure to cavity-creating mutations and its relation to the hydrophobic effect. Science 255:178-183.
206. Dewar MJS, Stewart JJP (1984). A new procedure for calculating molecular polarizabilities: Applications using MNDO. Chem Phys Lett 111:416-420.
207. Honig B, Sharp K, Yang A-S (1993). Macroscopic models of aqueous solutions: Biological and chemical applications. J Phys Chem 97:1101-1109.113.
208. Smithrud DB, Diederich F (1990). Strength of molecular complexation of apolar solutes in water and organic solvents is predictable by linear free-energy relationships: A general model for solvation effects on apolar binding. J Am Chem Soc 112:339-343.
209. Chothia C, Janin J (1975). Principles of protein-protein recognition. Nature 256:705-708.
210. Bohl M (1992). Molecular Structure and Biological Activity of Steroids. CRC Press, Boca Raton, Florida, p. 144.
211. Mueller G, Kim U-H (1978). Displacement from estrogen receptors by simple alkyl phenols. Endocrinology (Baltimore) 102: 1429-1435.
212. Marshall G (1987). Computer-aided drug design. Ann Rev Pharmacol Toxicol 27:193-213.
213. Durani S, Agarwal AK, Saxena R, Setty BS, Gupta RC, Kole PL, Ray S, Anand N (1979). Seco-oestradiols and some nonsteroidal oestrogens: Structural correlates of oestrogenic action. J Steroid Biochem 11:67-77.
214. Rosen P, Boris A, Oliva G (1980). Synthesis and biological activity of 15-oxaestranes. J Med Chem 23:329-330.
215. Simon Z, Mihalas GI, Caspi E (1984). Structure-binding affinity correlations for iodo-and selenoestrogen analogs and mapping of the estrogen receptor by the MTD-method. Rev Roum Chem 29:83-97.
216. Ikeda M (1982). Identification of thiol group at the estrogen binding site on the cytoplasmic receptor from rabbit uterus by affinity labeling. Biochiom Biophys Acta 718:66-73.
217. Fitch AN, Cockcroft JK (1990). A new structure for the low-temperature phase of solid hydrogen sulphide. J Chem Soc Chem Comm: 515-516.
218. Rosei MA (1988). SH vibrational frequency and hydrogen bond in biological thiols: A critical analysis, Physiol Chem Phys Med NMR 20:189-191.
219. Other researchers have supported the existence of thiol hydrogen bonding; see Paul IC (1974). Structural chemistry of the thiol group. In: Patai S (ed), The Chemistry of the Thiol Group. Wiley, London, pp. 111-161.
220. Simons SS, Pumphrey JG, Rudikoff S, Eisen H (1987). Identification of cysteine 656 as the amino acid of hepatoma tissue culture cell glucocorticoid receptors that is covalently labeled by dexamethasone 21-mesylate. J Biol Chem 262:9676-9680.
221. Reese JC, Wooge CH, Katzenellenbogen (1992). Identification of two cysteines closely positioned in the ligand-binding pocket of the human estrogen receptor: Roles in ligand binding and transcriptional activation. Molec Endocrinol 6:2160-2166.
222. Jensen EV, Hurst DJ, DeSombre ER, Jungblut PW (1967). Sulfhydryl groups and estradiol-receptor interaction. Science 158:385-387.
223. Ratajczak T, Hähnel R (1974). The protection, stabilization and reactivation of estradiol receptors in human myometrial cytosol. Biochim Biophys Acta 338:104-107.
224. Reese JC, Katzenellenbogen BS (1991). Mutagenesis of cysteines in the hormone binding domain of the human estrogen receptor. J Biol Chem 266:10,880-10,887.
225. Fersht AR, Dingwall C (1979). Cysteinyl-tRNA synthetase from Escherichia coli does not need an editing mechanism to reject serine and alanine. High binding energy of small groups in specific molecular interactions. Biochemistry 18:1245-1249.
226. Pakdel F, Katzenellenbogen BS (1992). Human estrogen receptor mutants with altered estrogen and antiestrogen discrimination. J Biol Chem 267:3429-3437.
227. Ekena K, Weis KE, Katzenellenbogen JA, Katzenellenbogen BS (1996). Identification of amino acids in the hormone-binding domain of the human estrogen receptor important in estrogen binding. J Biol Chem 271:20,053-20,059.
228. Hegy GB, Shakleton CHL, Carlquist M, Bonn T, Engström O, Sjöholm P, Witkowska HE (1996). Carboxymethylation of the human estrogen receptor ligand-binding domain-estradiol complex: HPLC/ESMS peptide mapping shows that cysteine 447 does not react with iodoacetic acid. Steroids 61:367-373.
229. Muldoon TG (1980). Molecular and functional anomalies in the mechanism of the estrogenic action of 4-mercuri-17β-estradiol. J Biol Chem 255:1358-1366.
230. Puca GA, Bresciana F (1970). Binding activity of oestrogen receptors destroyed by iodination. Nature 225:1251-1252.
231. Baker ME, Sklar DH, Terry LS, Hedges MR (1985). Diethyl pyrocarbonate, a histidine selective reagent, inhibits estrogen binding to receptor protein in rat uterus cytosol. Biochem Int 11:233-238.
232. Borgna J-L, Scali J (1988). Differential inhibition of estrogen and antiestrogen binding to the estrogen receptor by diethylpyrocarbonate. J Steroid Biochem 31:427-436.
233. Borgna J-L, Scali J (1991). Differential interaction of estrogens and antiestrogens at the 17β-hydroxy or counterpart functions with the estrogen receptor. Eur J Biochem 199:575-585.
234. Koffman B, Modarress KJ, Beckerman T, Bashirelahi N (1991). Evidence for involvement of tyrosine in estradiol binding by rat uterus receptor. J Steroid Biochem Molec Biol 38:135-139.
235. Shirley BA, Stanssens P, Hahn U, Pace CN (1992). Contribution of hydrogen bonding to the conformational stability of ribonuclease T1. Biochemistry 31:725-732.
236. Castoria G, Migliaccio A, Green S, Di Domenico M, Chambon P, Auricchio F (1993). Properties of a purified estradiol-dependent calf uterus tyrosine kinase. Biochemistry 32:1740-1750.
237. Arnold SF, Obourn JD, Jaffe H, Notides AC (1995). Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by Src family tyrosine kinases in vitro. Mol Endocrin 9:24-33.
238. Gantchev TG, Ali H, van Lier JE (1994). Quantitative-structure-activity relationships/comparative molecular field analysis (QSAR/CoMFA) for receptor-binding properties of halogenated estradiol derivatives. J Med Chem 37:4164-4176.
239. Sufrin Jr, Dunn DA, Marshall GR (1981). Steric mapping of the L-methionine binding site of ATP-L-methionine-S-adenosyl-tranferase. Molec Pharmacol 19:307-313.
240. Kym PR, Anstead GM, Pinney KG, Wilson SR, Katzenellenbogen JA (1993). Molecular structures, conformation analysis, and preferential modes of binding of 3-aroyl-2-arylbenzo[b]thiophene estrogen receptor ligands: LY117018 and aryl azide photoaffinity labeling analogs. J Med Chem 36:3910-3922.
241. Free SM Jr, Wilson JW (1964). A mathematical contribution to structure-activity studies. J Med Chem 7:395-399.
242. Williams RJP (1977). Flexible drug molecules and dynamic receptors. Angew Chem Int Ed Eng 16:766-777.
243. Herron JN, Kranz DM, Jameson DM, Voss EW Jr (1986). Thermodynamic properties of ligand binding by monoclonal antifluorescyl antibodies. Biochemistry 25:4602.
244. Lewis DFV, Parker MG, King RJB (1995). Molecular modeling of the human estrogen receptor and ligand interactions based on site-directed mutagenesis and amino acid sequence homology. J Steroid Biochem Molec Biol 52:55-65.
245. Lemesle-Varloot L, Ojasoo T, Mornon JP, Raynaud JP (1992). A model for the determination of the 3D-spatial distribution of the functions of the hormone-binding domain of receptor that bind 3-keto-4-ene steroids. J Steroid Biochem Molec Biol 41:369-388.
246. Goldstein RA, Katzenellenbogen JA, Luthey-Schulten ZA, Seielstad DA, Wolynes PG (1993). Three-dimensional model for the hormone binding domains of steroid receptors. Proc Natl Acad Sci USA 90:9949-9953.
247. Cheng S-Y, Ransom SC, McPhie P, Bhat MK, Mixson J, Weintraub BD (1994). Analysis of the binding of 3,3′,5-triiodo-L-thyonine and its analogues to mutant human β1 thyroid hormone receptors: A model of the hormone binding site. Biochemistry 33:4319-4326.
248. Bohl M (1987). Molecular mechanics investigation on side-chain conformations of a 17α-ethyl-17β-hydroxy steroid with regard to receptor binding. Z Naturforsch 42c:221-224.